IAS 2015: START Trial Provides Definitive Evidence of Benefits of Early HIV Treatment (Dr. Julio Montaner)

People who start antiretroviral therapy (ART) immediately after an HIV diagnosis — while their CD4 T-cell count is still high — rather than waiting until it falls below 350 cells/mm3 have a significantly lower risk of illness and death, according to long-awaited findings from the START trial presented at the 8th International AIDS Society Conference this week in Vancouver and published simultaneously in the July 20 advance edition of the New England Journal of Medicine.

HIV-AIDS experts call for governments worldwide to commit to immediate treatment

Experts on HIV-AIDS gathered in Vancouver are calling on political leaders worldwide to take action to help end the global epidemic.

Doctors call for wider use of drug that can prevent HIV infection (Dr. Julio Montaner)

International HIV/AIDS experts meeting in Vancouver are calling for wider use of a drug that can prevent HIV infection among those who engage in high-risk sex and are not infected with the virus.

But there are unanswered questions about the one-pill-a-day preventive treatment, including who should pay and whether broad use of it could fuel a surge in already-rampant levels of sexually transmitted infections (STIs) like gonorrhea, chlamydia and syphilis.

The science is in. And Insite works. (BC Centre for Excellence in HIV/AIDS)

With his steel-grey hair and spectacles, he looks more like a country doctor than a trouble-maker, yet here is Dr. Julio Montaner cracking open what Health Minister Rona Ambrose and indeed the entire federal Conservative government consider the very gates of hell.

B.C. government kicks off AIDS conference with funding announcement (BC Centre for Excellence in HIV/AIDS)

The B.C. government said it will put $2 million toward the Hope to Health Research Centre as a three-day international conference on the latest in HIV-related research opened Sunday in Vancouver.

B.C. researchers on the leading edge of the fight against HIV/AIDS (Dr. Julio Montaner)

Sixteen-year-old Nicole Ticea has wasted no time in throwing her considerable brains into the fight against AIDS.

The Vancouver high school student has launched her own company to develop a low-cost HIV test designed to give early-stage proof of whether a person has been infected with the AIDS virus.

Dr. Julio Montaner, director of the B.C. Centre for Excellence in HIV/AIDS and conference co-chair, says B.C. has developed a strategy that can beat the epidemic if the world’s governments make the financial commitment.

Paul Luke reports.

Ottawa shunning B.C. lead on AIDS (Dr. Julio Montaner)

B.C.’s successful policies for fighting HIV/AIDs are increasingly being adopted by other countries, but not by the Canadian government, says the director for the B.C. Centre for Excellence in HIV/AIDS.

B.C.’s success halting AIDS epidemic seen as a model for others (Dr. Julio Montaner)

When 6,000 international experts in HIV/AIDS start arriving in Vancouver today for a biennial conference, many will optimistically talk about this point in time as pivotal.

As the beginning of the end of AIDS.

HIV Treatment as Prevention Saves Money Over Long Term (Dr. Bohdan Nosyk)

Expanding treatment as prevention is not only cost-effective over the long term, but when productivity gains are considered, it is cost-saving, a new study indicates.

In British Columbia, the only Canadian province that has adopted complete access, expanding antiretroviral therapy could save up to $65.5 million by 2035, said lead author Bohdan Nosyk, PhD, from the British Columbia Centre for Excellence in HIV/AIDS, who is St. Paul's Hospital CANFAR Chair in HIV/AIDS Research at Simon Fraser University in Vancouver, British Columbia.

Expanding Access to HAART Saves Millions in Health Care and Productivity Costs (Dr. Julio Montaner, BC-CfE)

A study published in The Lancet HIV by the BC Centre for Excellence in HIV/AIDS (BC-CfE) shows expanding Treatment as Prevention® (TasP®) could save up to $66.5 million over the next 25 years, compared with a scenario with reduced access to antiretroviral medication. The study finds expanded access to highly active antiretroviral therapy (HAART) has more than offset the additional costs of treatment, resulting in improved health outcomes and cost-savings.



Subscribe to RSS - HIV/AIDS